EGF and neoplasm: The ability of DOK2 to inhibit EGF-induced activity of wild-type RAS and the fact that DOK2 is constitutively bound to RASA1 in cells harboring EGFRL858R suggest that at least part of DOK2’s tumor suppressive function is to suppress RAS activation via RASA1.